{"id":"symbicort-pmdi-budesonide-hfa-pmdi","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":"5-10","effect":"Oral candidiasis"},{"rate":null,"effect":"Hoarseness"}]},"_chembl":{"chemblId":"CHEMBL1370","moleculeType":"Small molecule","molecularWeight":"430.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide suppresses inflammatory cytokine production and immune cell recruitment in the airways, reducing mucus production, airway edema, and bronchial hyperresponsiveness. The pMDI (pressurized metered-dose inhaler) and HFA (hydrofluoroalkane) formulations deliver the drug directly to the lungs for local anti-inflammatory effects with minimal systemic absorption.","oneSentence":"Budesonide is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:57.823Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT01136655","phase":"PHASE2","title":"A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Asthma","enrollment":54},{"nctId":"NCT00419952","phase":"PHASE3","title":"A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Asthma","enrollment":742},{"nctId":"NCT00419757","phase":"PHASE3","title":"An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Asthma","enrollment":558},{"nctId":"NCT00536913","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Asthma","enrollment":107},{"nctId":"NCT00651768","phase":"PHASE3","title":"Titratable Dosing in Moderate to Severe Asthmatics","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-08","conditions":"Asthma","enrollment":570},{"nctId":"NCT00646009","phase":"PHASE3","title":"Symbicort Onset of Action 2","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-03","conditions":"Asthma","enrollment":48},{"nctId":"NCT00449501","phase":"PHASE3","title":"A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03","conditions":"Asthma","enrollment":134},{"nctId":"NCT00449527","phase":"PHASE3","title":"A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03","conditions":"Asthma","enrollment":123},{"nctId":"NCT00646620","phase":"PHASE3","title":"Symbicort Onset of Action 1","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":48},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Symbicort pMDI + budesonide HFA pMDI","genericName":"Symbicort pMDI + budesonide HFA pMDI","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}